Regulatory Resilience: How manufacturers can cope with FDA uncertainties and EU challenges

Deregulation at the FDA? High hurdles in the EU? Where should the journey take you when political events come thick and fast and market access conditions change overnight? Manufacturers of medical devices face a complex question: US market through the supposedly simpler 510(k) pathway, EU market with the complex MDR (Medical Device Regulation (EU) 2017/745) / IVDR (In Vitro Diagnostic Medical Device Regulation (EU) 2017/746), or perhaps alternatives such as Asia, Latin America, or maybe Canada?

Reports from the United States have intensified this discussion in recent weeks:

• The FDA is withdrawing from various MedTech standardization committees, which could lead to a greater decoupling from global standards.
• Trump's "10-for-1" order puts additional pressure on the FDA: For every new regulation, 10 existing ones must be eliminated.
• Nonetheless, FDA enforcement remains (partially) active: The agency reportedly continues to take action in cases of quality deficiencies or blatant violations.
• The Trump administration unexpectedly terminates FDA employees and partially rehires them a few days later which should at least temporarily alleviate bottlenecks. But is this enough to compensate for the loss of expertise – not to mention the loss of trust?

Against this backdrop, we would like to show you why "regulatory resilience" – the ability to robustly and flexibly handle changing regulations – is so important for your company and which scenarios may arise for German or EU manufacturers.

The dilemma for you as a manufacturer

Because the MDR/IVDR is considered complex and expensive, many companies had hoped to reach their goal faster in the USA. However, staff cuts, political deregulation targets, and the withdrawal from standardization committees are now causing growing uncertainty among EU manufacturers. Although a less stringent review process may be advantageous in certain cases in the short term, it can also raise the following risks:

• Quality and reputational risks: If the FDA loses reputation or neglects standards in the long term, the value of an "FDA approved" seal may decrease.
• Unpredictable processes: Lack of personnel or frequently changing requirements can delay procedures or lead to patchwork regulations. The recently reported partial withdrawal from key standardization committees adds to concerns that global harmonization is losing momentum.
• Continuity at risk: Although some employees have been rehired, skepticism prevails in professional circles: experience-based knowledge may already be lost and the political pressure towards deregulation remains.

"Regulatory resilience" is the key

What do we mean by this?

Regulatory resilience means that your company is set up in such a way that it can respond quickly and safely to changing requirements – whether in the USA, the EU, or elsewhere. Specifically, this means:

• Structured, digital documentation: "Think in data, not in documents." If you can adapt your regulatory data and the processes in your quality management system (QMS) to new regulatory requirements at any time, you are less susceptible to regulatory volatility.
• Access to multiple markets in view: Focusing solely on the US market can be risky if the FDA becomes unreliable. As an alternative or in parallel, obtaining EU approval (MDR(IVDR) or entering markets such as Canada, Latin America, or Asia could be a sensible strategy.
• Developing long-term scenarios instead of making ad-hoc decisions: Those who benefit from a more lax authority today may face difficulties with product liability or global marketing tomorrow.

What has happened so far – and what is new

Deregulation vs. rehiring

• Until recently, there were talks of extensive layoffs at the FDA. Currently, some of these are being reversed, which could slightly relieve the agency’s staff.
• The fact that some of the dismissed employees are now returning will only solve the problems to a limited extent, as it may not be possible to rebuild the same depth of expertise and experience.
• The "10-for-1" order is still in force: for every new regulation, ten old ones are to be deleted. This could result in the regulatory authorities being very hesitant to publish new regulations, thereby preventing alignment with global regulatory standards. On the other hand, there could also be a significant streamlining of the regulatory environment in the USA.

Withdrawal from standardization committees

• Standardization is essential for the global medtech industry as it facilitates the coordination of standards (e.g., ISO 13485, IEC 60601). If the FDA withdraws from these committees, US-specific requirements may increasingly deviate from international norms.
• For manufacturers, this means potentially higher costs, as the technical documentation, once written, may then not be used 1:1 for the FDA.

Also important

• The MDR and IVDR remain demanding, but despite all the criticism about speed and costs, they have the advantage of a certain degree of stability and global recognition.
• In other regions (Canada, Latin America, Asia), approval procedures are modernized, in some cases even offering higher growth opportunities or less bureaucracy, which could be an alternative.

Possible Scenarios for EU Manufacturers

Scenario A: Focus on the US market

• Pros: Known, clearly structured procedures (e.g., 510 (k)), provided nothing changes.
• Cons: Uncertainty due to employee turnover, lack of long-term commitment to standardization, and risk of future liability issues if quality standards no longer apply.

Scenario B: Strong focus on the MDR/IVDR

• Pros: Reliable process; high global recognition, especially regarding quality.
• Cons: Higher cost peaks, longer development cycles, limited capacity at notified bodies.

Scenario C: Alternatives in Canada, Latin America, and Asia

• Pros: Growing markets, in some cases more efficient approval pathways (e.g., in India for low-cost devices or in Brazil for certain high-risk products).
• Cons: Possible cultural and linguistic barriers, complex customs and import regulations, sometimes a lack of harmonization between countries.

Scenario D: A combination of multiple markets

• Pros: More security through diversification. For example, serving both the EU and Canada provides a solid base and allows you to target the US market later if needed. The MDSAP procedure is also useful here, as it allows you to cover several regions with just one audit, keeping the door open to adding additional markets later (e.g., Japan or – under the current status - the USA).
• Cons: Higher initial costs, as the MDSAP audit can be extensive and thorough. Also, not all relevant markets are part of MDSAP (e.g., the EU, India, or Latin America except Brazil). However, the extra effort is worthwhile precisely if you want to build and expand your regulatory resilience in this area.

Achieving "regulatory resilience" with Metecon

Our Metecon team specializes in making your market access robust and future-proof. This means:

• A 360° analysis of your product portfolio: Which requirements apply in different markets? Where are your opportunities and potential pitfalls?
• Data management instead of paper mountains: We rely on digitized, interconnected systems so that you can react flexibly to new regulations – whether in the USA, the EU, or other regions.
• Many years of experience: Our experts continuously monitor current developments (FDA, EU, MDSAP countries) and can recognize trends early on.
• Individual strategy: Whether you are a mid-sized company or a large corporation, from low-risk to high-risk products – we will find the mix that works for you.

The FDA may currently be bringing back staff, but it remains in a state of upheaval – particularly due to political requirements and the withdrawal from international standardization initiatives. At the same time, the MDR offers planning security but is not an easy path. Markets such as Asia, Brazil, and Canada can also be exciting, provided you are well-prepared.

"Regulatory resilience" means that you are not solely dependent on a single authority or market. With a robust quality management system, digitized data, and multiple potential approval routes, you will remain agile in turbulent times –securing your competitive position in the long term.

We will help you to develop a tailor-made strategy.

Contact us - and strengthen your company's regulatory resilience!